I am a buyer down here, price is hard to pass up.
Recent CRDF News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 10:13:50 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 10:11:34 PM
- Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/28/2026 08:01:00 PM
- Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity • GlobeNewswire Inc. • 04/27/2026 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:45:10 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:44:20 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/23/2026 08:41:21 PM
- Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026 • GlobeNewswire Inc. • 04/21/2026 02:00:00 PM
- Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting • GlobeNewswire Inc. • 04/17/2026 08:01:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 12:08:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 08:03:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 08:01:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 08:10:09 PM
- Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth • GlobeNewswire Inc. • 04/09/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:16:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:15:28 PM
- Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer • GlobeNewswire Inc. • 03/20/2026 11:00:00 AM
- Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting • GlobeNewswire Inc. • 03/19/2026 11:00:00 AM
- Cardiff Oncology to Participate in Three Upcoming Investor Conferences • GlobeNewswire Inc. • 02/26/2026 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 01:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 10:09:22 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/24/2026 10:07:45 PM
- Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update • GlobeNewswire Inc. • 02/24/2026 09:30:00 PM
- Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/19/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 09:02:04 PM
